1/4
Clinical efficacy of intravenous followed by oral azithromycin monotherapy in hospitalized patients with community-acquired pneumonia. The azithromycin Intravenous clinical trials group / J Plouffe; DB Schwartz; A Kolokathis; BW Sherman; PM Arnow; JA Gezon.-- p. 1796-802.-- En: Antimicrob Agents Chemother.-- 44, 7 (2000)
Notas de Contenido:
Material no impreso
ADMINISTRACION ORAL   ADOLESCENTE   ADULTO   ANCIANO   ANTIBIOTICOS MACROLIDOS   AZITROMICINA   INFECCIONES COMUNITARIAS ADQUIRIDAS   FEMENINO   HOSPITALIZACION   HUMANO   INFUSIONES INTRAVENOSAS   MASCULINO   TESTS DE SENSIBILIDAD MICROBIANA   MEDIA EDAD   RESISTENCIA A PENICILINA   NEUMONIA   STREPTOCOCCUS PNEUMONIAE
Ubicación: Centro de Información y Documentación (CANIA)   
Solicite el material por este código: AS-5746
Tipo de Material:
Separata

    The purpose of this study was to evaluate intravenous (i.v.) azithromycin followed by oral azithromycin as a monotherapeutic regimen for community-acquired pneumonia (CAP). Two trials of i.v. azithromycin used as initial monotherapy in hospitalized CAP patients are summarized. Clinical efficacy is reported from an open-label randomized trial of azithromycin compared to cefuroxime with or without erythromycin. Bacteriologic and clinical efficacy results are also presented from a noncomparative trial of i.v. azithromycin that was designed to give additional clinical experience with a larger number of pathogens. Azithromycin was administered to 414 patients: 202 and 212 in the comparative and noncomparative trials, respectively. The comparator regimen was used as treatment for 201 patients; 105 were treated with cefuroxime alone and 96 were given cefuroxime plus erythromycin. In the comparative trial, clinical outcome data were available for 268 evaluable patients with confirmed CAP at the 10- to 14-day visit, with 106 (77%) of the azithromycin patients cured or improved and 97 (74%) of the comparator patients cured or improved. Mean i.v. treatment duration and mean total treatment duration (i.v. and oral) for the clinically evaluable patients were significantly (P < 0.05) shorter for the azithromycin group (3.6 days for the i.v. group and 8.6 days for the i.v. and oral group) than for the evaluable patients given cefuroxime plus erythromycin (4.0 days for the i.v. group and 10.3 days for the i.v. and oral group). The present comparative study demonstrates that initial therapy with i.v. azithromycin for hospitalized patients with CAP is associated with fewer side effects and is equal in efficacy to a 1993 American Thoracic Society-suggested regimen of cefuroxime plus erythromycin when the erythromycin is deemed necessary by clinicians.

Ver separata




2/4
El problema de las bacterias resistentes en el tratamiento de la otitis media aguda = The problem of resistant bacteria for the management of acute otitis media / ED Barnett; JO Klein.-- pp. 473-80.-- En: Clínicas Pediátricas de Norteamérica.-- 3 (1995)
Notas de Contenido:
Revista en estanteria
ENFERMEDAD AGUDA   AGENTES ANTIBACTERIANOS   NIÑO   INFECCIONES POR HAEMOPHILUS   HAEMOPHILUS INFLUENZAE   MORAXELLA (BRANHAMELLA) CATARRHALIS   OTITIS MEDIA   RESISTENCIA A PENICILINA   INFECCIONES NEUMOCOCICAS   STREPTOCOCCUS PNEUMONIAE
Ubicación: Centro de Información y Documentación (CANIA)   
Tipo de Material:
Separata

    En este artículo se exponen los patrones de susceptibilidad actuales de cada uno de los tres patógenos citados, y se señalan diversas opciones para tratar la entidad que nos ocupa.




3/4
Neumococos resistentes a los antibióticos = Antibiotic-resistant pneumococci / JR Schreiber; MR Jacobs.-- pp. 481-98.-- En: Clínicas Pediátricas de Norteamérica.-- 3 (1995)
Notas de Contenido:
Revista en estanteria
AGENTES ANTIBACTERIANOS   RESISTENCIA MICROBIANA A LAS DROGAS   MENINGITIS NEUMOCOCICA   RESISTENCIA A PENICILINA   INFECCIONES NEUMOCOCICAS   STREPTOCOCCUS PNEUMONIAE   SALUD MUNDIAL
Ubicación: Centro de Información y Documentación (CANIA)   
Tipo de Material:
Separata

    Streptococcus pneumoniae es una de las causas más frecuentes de enfermedad focal y sistemática grave en los niños. Desde hace muchos años se sabe de la resistencia del neumococo a los antibióticos, pero sólo a últimas fechas la resistencia a la penicilina y otros antimicrobianos se ha generalizado en muchas partes del mundo, incluido Estados Unidos donde la prevalencia de tales microorganismos va en rápido aumento. La resistencia d elos neumococos a estos fármacos ha obligado a una revaloración de la terapia empírica contra las infecciones causadas por ellos, y ha dado un carácter más urgente a la necesidad de mejorar las vacunas antineumocócicas para niños.




4/4
Resistencia de los estreptococos del grupo A a los antibióticos = Antibiotic resistance in group A streptococci / MA Gerber.-- pp. 499-510.-- En: Clínicas Pediátricas de Norteamérica.-- 3 (1995)
Notas de Contenido:
Revista en estanteria
AGENTES ANTIBACTERIANOS   RESISTENCIA MICROBIANA A LAS DROGAS   RESISTENCIA A PENICILINA   STREPTOCOCCUS PNEUMONIAE
Ubicación: Centro de Información y Documentación (CANIA)   
Tipo de Material:
Separata

    Although erythromycin resistance in GABHS has been a major problem in Japan and in Finland, it has not been a problem in the United States. The susceptibility of GABHS to the newer macrolide antibiotics seems to be similar to that of erythromycin. Comprehensive, community-wide programs to continuously monitor for erythromycin resistance in GABHS would be difficult to justify; however, because little is known about how erythromycin resistance in GABHS is acquired or spread, it would be reasonable to periodically monitor isolates of GABHS for erythromycin resistance. Despite more than four decades of use of penicillin in treating GABHS infections, no significant change has occurred in the in vitro susceptibility of GABHS to penicillin. The resurgence of severe, invasive GABHS infections and of acute rheumatic fever is not attributable to the emergence of strains of GABHS with increased resistance to penicillin. A substantial proportion of GABHS are currently resistant to tetracyclines, and these agents are inappropriate for treating GABHS infections....continúa.





4 Registros recuperados

Presentar con el formato: 

Ver selección       Limpiar selección